ClinicalTrials.gg
RecruitingNCT07441642Updated Nov 9, 2026

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Phase 2 interventional study of FWY003 and Placebo in Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Recruiting at 65 sites in 19 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 2026First sites in Argentina, Brazil and China10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Geographic Atrophy by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Geographic Atrophy · Novartis.

Planned enrollment
5th of 15
272 · median 158
Started
2026
the only one that year
Phase 2
4 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Geographic Atrophy by Novartis, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 2, and was the 15th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

1 of the 15 studies in Geographic Atrophy by Novartis is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Geographic Atrophy by Novartis, or all of them as a file.
02

Study summary

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Read the detailed description

This study is designed as a randomized, multi-center, double-masked, prospective study to characterize the dose response relationship, efficacy and safety of FWY003.

03

Conditions studied

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Keywords

  • FWY003
  • safety
  • tolerability
  • geographical atrophy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female participants ≥ 50 years of age.

  • A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.

    1. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)
    2. If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2
    3. Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy
  • ETDRS BCVA ≥ 35 letters (20/200) in the study eye.

Exclusion criteria

Exclusion Criteria:

  • A history of, or current evidence of, choroidal neovascularization (exudative MNV) in the study eye.
  • Previous cell or gene therapy in either eye.
  • Macular atrophy in either eye due to a cause other than AMD, such as Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.
  • Intraocular surgery, including cataract and vitreoretinal surgery, in the study eye within 3 months prior to Baseline.
  • Presence of significant media opacity, eye movement disorder (nystagmus), severe ptosis, extraocular motility restriction or head tremor, which in the opinion of the investigator, would prevent adequate fundus visualization or which in the opinion of the Reading Center could interfere with the assessment of study images.

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    FWY003 dose level 1

    Participants will receive FWY003 dose level 1

    Drug: FWY003

  • Experimental
    FWY003 dose level 2

    Participants will receive FWY003 dose level 2

    Drug: FWY003

  • Experimental
    FWY003 dose level 3

    Participants will receive FWY003 dose level 3

    Drug: FWY003

  • Placebo comparator
    Placebo

    Participants will receive placebo

    Drug: Placebo

Interventions

  • DrugFWY003

    FWY003 arm participants will receive a specific dose of FWY003

  • DrugPlacebo

    Placebo arm participants will receive placebo

06

What researchers measure

Primary outcomes

  1. Change of geographic atrophy (GA) lesion area in the study eye

    To evaluate the dose response relationship of FWY003 on GA lesion area in the study eye in participants with GA secondary to age-related macular degeneration (AMD).

    Time frame: From Baseline to Month 18

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of FWY003.

    Time frame: From first dose (Day 1) to Month 19

  2. Change in visual function measure by ETDRS (Regular Luminance) Best Corrected Visual Acuity (BCVA) in the study eye

    To assess the change in visual function over time by measuring Best Corrected Visual Acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart under normal lighting conditions. BCVA is the sharpest vision a person can achieve with optimal correction, such as glasses or contact lenses. The ETDRS eye chart is the standardized chart used in clinical trials.

    Time frame: Baseline through Month 18

  3. Change in visual function measure by ETDRS Low Luminance Visual Acuity (LLVA) in the study eye

    To assess the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual Acuity (LLVA) vision test. This test measures how well a person can see under low-light conditions. It is performed using the standard ETDRS eye chart.

    Time frame: Baseline through Month 18

  4. Change in visual function measure by Quantitative contrast sensitivity function (qCSF) under regular luminance in the study eye

    To assess the change in visual function by using a test called the quantitative Contrast Sensitivity Function (qCSF). qCSF checks how faint a pattern a person can see, and how that changes for large vs. small details.

    Time frame: Baseline through Month 18

  5. Change in visual function measure by Low Contrast quantitative Visual Acuity (LCqVA) under regular luminance in the study eye

    To assess the change in visual function using a test called Low Contrast quantitative Visual Acuity (LCqVA). LCqVA is visual acuity test where letters on the chart are printed with reduced contrast. The test is performed in normal lighting conditions.

    Time frame: Baseline through Month 18

  6. Change in visual function measure by LCqVA under low luminance in the study eye

    To assess the change in visual function in dim-light conditions using a test called Low Contrast quantitative Visual Acuity (LCqVA). This test measures how well a person can read low-contrast letters. The test is performed with reduced luminance (making the environment darker).

    Time frame: Baseline through Month 18

  7. Proportion of participants with ≥15 letters loss

    To measure how many participants in a study lose 15 or more letters on a visual test

    Time frame: Baseline through Month 18

  8. Change in area of total and partial ellipsoid zone (EZ) attenuation in the macula in the study eye

    To assess the effect of FWY003 on photoreceptor parameters in the study eye.

    Time frame: Baseline through Month 18

  9. Plasma concentrations of FWY003

    To assess the pharmacokinetic profile of FWY003.

    Time frame: Baseline through Month 18

  10. Rate of change of GA lesion area (square-root transformed) in the study eye

    To assess the rate of change in GA lesion area in the study eye.

    Time frame: Baseline through Month 18

  11. Change of GA lesion area (square-root transformed)

    To assess the effect of FWY003 on GA lesion area.

    Time frame: Baseline through Month 12

07

Study locations

65 of 65 sites recruiting
  • Salehi Retina Institute
    Huntington Beach, California 92647, United States
    Recruiting
  • Retinal Consultants Medical Group Inc
    Sacramento, California 95841, United States
    Recruiting
    • Daniel Ortiz · Contactortizd@retinalmd.com · +1 916 339 3655
    • Margaret Chang · Principal investigator
  • California Retina Consultants
    Santa Barbara, California 93103, United States
    Recruiting
  • Advanced Research LLC
    Boynton Beach, Florida 33437, United States
    Recruiting
  • Advanced Research LLC
    Deerfield Beach, Florida 33064, United States
    Recruiting
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33711, United States
    Recruiting
    • Logan Wilson · Contactlwilson@rvaf.com · +1 727 323 0077
    • David Eichenbaum · Principal investigator
  • Retina Associates New Orleans
    Metairie, Louisiana 70001, United States
    Recruiting
  • Opthamalic Consultants of Boston
    Boston, Massachusetts 02114, United States
    Recruiting
    • Haylie Carlon · Contacthcarlon@eyeboston.com · +1 617 314 2636
    • Jeffrey S Heier · Principal investigator
  • NJ Retina
    Toms River, New Jersey 08755, United States
    Recruiting
    • Andy Merino · Contactamerino@njretina.com · +1 732 906 1887
    • Howard Fine · Principal investigator
  • New York Eye and Ear Infirmary of Mount Sinai
    New York, New York 10003, United States
    Recruiting
    • Katy Tai · Contactktai@nyee.edu · +1 212 979 4251
    • Richard Rosen · Principal investigator
  • Columbia University Medical Center
    New York, New York 10032, United States
    Recruiting
  • Erie Retina Research LLC
    Erie, Pennsylvania 16505, United States
    Recruiting
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Retina Consultants TX Rsrch Ctr
    Bellaire, Texas 77401, United States
    Recruiting
  • Retina Consultants of Houston PA
    Houston, Texas 77030, United States
    Recruiting
  • Retina Consultants of Texas
    Katy, Texas 77494, United States
    Recruiting
  • Novartis Investigative Site
    Rosario, De Santa Fe B7602, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, C1008AAP, Argentina
    Recruiting
  • Novartis Investigative Site
    Caba, C1056, Argentina
    Recruiting
  • Novartis Investigative Site
    Albury, New South Wales 2640, Australia
    Recruiting
  • Novartis Investigative Site
    Parramatta, New South Wales 2150, Australia
    Recruiting
  • Novartis Investigative Site
    Strathfield, New South Wales 2135, Australia
    Recruiting
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
    Recruiting
  • Novartis Investigative Site
    Serra, Espírito Santo 29160-750, Brazil
    Recruiting
  • Novartis Investigative Site
    Blumenau, Santa Catarina 89010-204, Brazil
    Recruiting
  • Novartis Investigative Site
    Sofia, 1618, Bulgaria
    Recruiting
  • Novartis Investigative Site
    London, Ontario N6A 4L8, Canada
    Recruiting
  • Novartis Investigative Site
    Ottawa, Ontario K2B 7E9, Canada
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200080, China
    Recruiting
  • Novartis Investigative Site
    Medellín, Antioquia 050001, Colombia
    Recruiting
  • Novartis Investigative Site
    Barranquilla, Atlántico 080001, Colombia
    Recruiting
  • Novartis Investigative Site
    Prague, 100 34, Czechia
    Recruiting
  • Novartis Investigative Site
    Prague, 128 08, Czechia
    Recruiting
  • Novartis Investigative Site
    Lyon, Rhone 69004, France
    Recruiting
  • Novartis Investigative Site
    Créteil, 94000, France
    Recruiting
  • Novartis Investigative Site
    Dijon, 21000, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75940, France
    Recruiting
  • Novartis Investigative Site
    Ludwigshafen, Germany 67063, Germany
    Recruiting
  • Novartis Investigative Site
    Bonn, 53105, Germany
    Recruiting
  • Novartis Investigative Site
    Münster, 48145, Germany
    Recruiting
  • Novartis Investigative Site
    Tübingen, 72076, Germany
    Recruiting
  • Novartis Investigative Site
    Pécs, Baranya 7621, Hungary
    Recruiting
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
    Recruiting
  • Novartis Investigative Site
    Budapest, 1083, Hungary
    Recruiting
  • Novartis Investigative Site
    Florence, FI 50134, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20122, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20132, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00184, Italy
    Recruiting
  • Novartis Investigative Site
    Amagasaki, Hyōgo 6608550, Japan
    Recruiting
  • Novartis Investigative Site
    Kobe, Hyōgo 6500047, Japan
    Recruiting
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 1138655, Japan
    Recruiting
  • Novartis Investigative Site
    Chiyoda-ku, Tokyo 1018309, Japan
    Recruiting
  • Novartis Investigative Site
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-631, Poland
    Recruiting
  • Novartis Investigative Site
    Krakow, 31-070, Poland
    Recruiting
  • Emanuelli Research and Development Center LLC
    Arecibo, 00612, Puerto Rico
    Recruiting
    • Diane Perez Perez · Contactdperez@erdpr.com · +1 787 879 7722
    • Andres Emanuelli Anzalotta · Principal investigator
  • Novartis Investigative Site
    Cluj-Napoca, Cluj 400006, Romania
    Recruiting
  • Novartis Investigative Site
    Bucharest, 011658, Romania
    Recruiting
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
    Recruiting
  • Novartis Investigative Site
    Sant Cugat Del V, Barcelona 08190, Spain
    Recruiting
  • Novartis Investigative Site
    Burjassot, Valencia 46100, Spain
    Recruiting
  • Novartis Investigative Site
    Córdoba, 14012, Spain
    Recruiting
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
    Recruiting
  • Novartis Investigative Site
    London, NW10 7NS, United Kingdom
    Recruiting
  • Novartis Investigative Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
    Recruiting
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2029, 41 months after the start.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Aug 21, 2029
CompletionEst.
Aug 22, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first sites in Argentina, Brazil and China
Show 10 added (3 Argentina, 2 Brazil, 2 Japan, 1 United States, 1 China, 1 Colombia)
  • Novartis Investigative Site · Caba, Argentina
  • Novartis Investigative Site · Serra, Brazil
  • Novartis Investigative Site · Blumenau, Brazil
  • Novartis Investigative Site · Chiyoda-ku, Japan
  • Retina Associates New Orleans · Metairie, United States
  • Novartis Investigative Site · Rosario, Argentina
  • Novartis Investigative Site · CABA, Argentina
  • Novartis Investigative Site · Shanghai, China
  • Novartis Investigative Site · Medellín, Colombia
  • Novartis Investigative Site · Amagasaki, Japan
across 2 updates, Oct 13, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    6 sites added — first site in China
    Show 6 added (2 Argentina, 1 United States, 1 China, 1 Colombia, 1 Japan)
    • Retina Associates New Orleans · Metairie, United States
    • Novartis Investigative Site · Rosario, Argentina
    • Novartis Investigative Site · CABA, Argentina
    • Novartis Investigative Site · Shanghai, China
    • Novartis Investigative Site · Medellín, Colombia
    • Novartis Investigative Site · Amagasaki, Japan
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites added — first sites in Argentina and Brazil
    Show 4 added (2 Brazil, 1 Argentina, 1 Japan)
    • Novartis Investigative Site · Caba, Argentina
    • Novartis Investigative Site · Serra, Brazil
    • Novartis Investigative Site · Blumenau, Brazil
    • Novartis Investigative Site · Chiyoda-ku, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07441642
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 9, 2026
Primary completion
Aug 21, 2029 (estimated)
Completion
Aug 22, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion